The non-medical use of prescription drugs is thought to represent the fastest growing drug problem in the United States, and urologists aren't immune to it.
Early results with tanezumab (RN624), an investigational monclonal antibody against nerve growth factor, show promise for chronic bladder pain in interstitial cystitis.
New York—Management of metastatic, clear-cell renal cell carcinoma has been significantly advanced by the development of the oral small-molecule kinase inhibitors sunitinib malate (Sutent) and sorafenib (Nexavar), recent results from two large, international, randomized, double-blind, phase III trials indicate. Both studies appeared in the Jan. 11, 2007 issue of the New England Journal of Medicine (2007; 356:115-24 and 125-34).
Las Vegas—An investigational drug that acts on the central nervous system may work as a treatment for female sexual dysfunction (FSD), according to a recent study from New York Presbyterian Hospital/Weill Cornell Medical Center in New York. The drug, bremelanotide, is also being investigated for the treatment of erectile dysfunction in men.
Las Vegas—The best way to treat premature ejaculation (PE) is through a combination of sex therapy and pharmaceutical management, Michael A. Perelman, PhD, argued at the Sexual Medicine Society of North America fall meeting here.
The FDA has approved new labeling for sunitinib malate (Sutent) to include first-line treatment of advanced renal cell carcinoma. The labeling change is based on results of a large phase III trial that showed prolonged progression-free survival.
New York—The administration of sipuleucel-T (Provenge), an investigational immunotherapy designed to stimulate a patient's immune response, followed by docetaxel chemotherapy prolonged survival in men with asymptomatic androgen-independent prostate cancer (AIPC), according to a recently released study. Median survival in these men was 14 months longer than would have been predicted by a prostate cancer survival nomogram, said Daniel Petrylak, MD, associate professor of medicine and director of genitourinary oncology at Columbia Presbyterian Medical Center in New York.
San Francisco—A study at one of the largest health systems in Vancouver, British Columbia, has found that long-term care facilities have become a significant reservoir for resistance to fluoroquinolone antibiotics. The rise of resistance appears to be the result of the increased use of quinolones for empiric treatment of urinary tract infections and pneumonia in residents of these facilities.
Herbal supplements and other complementary therapies are surrounded by clinical and ethical issues, some involving urologists.
New York—Satraplatin, an oral platinum analog in late-stage development as second-line chemotherapy for hormone-refractory prostate cancer, has shown encouraging results in phase III trials, said Oliver Sartor, MD, associate professor of medicine at the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute, Boston. Dr. Sartor, who reviewed phase III results of the drug at the recent Chemotherapy Foundation Symposium here, said satraplatin is one of the most promising new agents under study for hormone-refractory disease.